Podcast Atlas

Founder Mode: Jen Herbach, Founder & CEO, Adventris Pharmaceuticals

source Episode summary Updated 2026-07-14 Tags: Podcast, Startups, Y-Combinator, Founder-Mode, Biotech, Oncology

Summary

This The Social Radars YC offsite episode has Jen Herbach explain Adventris Pharmaceuticals through both biotech strategy and Founder Mode. The scientific branch centers on Cancer Vaccine Platform work aimed at helping the immune system recognize cancer cells, with KRAS Oncology Target as the first cross-cancer target and localized pancreatic cancer as the initial treatment setting. The operating branch shows how Brian Chesky’s founder-mode talk pushed Jen closer to lab execution, team accountability, and Biotech Founder Control around SAFEs, board seats, and scientific conviction.

Key Claims

  • Adventris Pharmaceuticals is described as a Winter 2023 Y Combinator company making cancer vaccines.
  • Jen frames cancer as partly an immune-recognition failure: the immune system has not recognized uncontrolled cells as foreign.
  • The company starts with KRAS Oncology Target, which Jen calls a driver mutation involved in more than 30% of cancers, especially lung, colon, and pancreatic cancer.
  • Adventris is first focused on localized pancreatic cancer patients who may relapse into metastatic incurable disease.
  • Jen says the long-term ambition is prevention, including a KRAS vaccine that could prevent about 30% of all cancers if the premise works.
  • She says expected side effects are minimal and comparable to ordinary infectious-disease vaccines such as COVID or flu shots.
  • The company is finalizing the product for patients and plans to submit an IND to the FDA before dosing first patients in early 2027.
  • Jen studied science, considered becoming an oncologist, then pursued graduate school, business school, and life-sciences commercialization work before founding the company with a college roommate and lab partner who became an oncologist.
  • Jen says YC helped Adventris learn company building, investor storytelling, and how to keep the company in the driver’s seat with investors.
  • Brian Chesky’s founder-mode talk changed how Jen managed the science: she began getting closer to lab details, required daily end-of-day standups, and raised accountability.
  • Two team members left after the accountability shift; Jen says the remaining and later-hired team members became stronger and more productive.
  • YC advice to use SAFEs and decline an investor board seat later mattered when an investor disagreed with the company’s scientific strategy.
  • Jen says the absence of investor board control let Adventris evaluate the advice, reject it from product and scientific perspectives, and make later delivery-platform decisions quickly.
  • The company later added an independent biotech board member chosen by the founders rather than accepting an investor board seat.

Key Quotes

“glasses” - Jen’s metaphor for making cancer cells visible to the immune system.

“accountability partner” - one proposed reframing of close founder involvement.

“best for patients” - how Jen describes the company’s decision standard.

Connections

Contradictions

  • No direct contradiction found against existing wiki content. The source itself has a naming inconsistency: the metadata title says Adventris Pharmaceuticals, while the body repeatedly spells the company “Adventress.”

Source Notes

  • Ingested from the TSR-YCOffsite-JenHerbach-v1-Audio Markdown export in the podcastatlas episode corpus.
  • The entity page uses the title spelling Adventris Pharmaceuticals while preserving the source body’s alternate spelling as a note.